Type 1 Diabetes TrialNet
Type 1 Diabetes TrialNet (TrialNet) comprises an international network of researchers established in 2021 for the purpose of conducting studies designed to evaluate new approaches to prevent, delay and reverse the progression of type 1 diabetes. These include interventions designed to decrease beta-cell destruction and/or enhance beta-cell survival. TrialNet engages in new onset diabetes trials to assess safety and to determine whether interventions can lead to preservation of C-peptide. Positive results from new onset trials are then evaluated for whether the intervention can be brought into the prevention space for further evaluation. Other TrialNet goals include characterization of diabetes risk and pathophysiology through genetic, immunologic, and metabolic studies in participants... (for more see dbGaP study page.)